These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 26717150)

  • 1. Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.
    Hoffmann LS; Kretschmer A; Lawrenz B; Hocher B; Stasch JP
    PLoS One; 2015; 10(12):e0145048. PubMed ID: 26717150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
    Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
    Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta.
    Korkmaz S; Loganathan S; Mikles B; Radovits T; Barnucz E; Hirschberg K; Li S; Hegedüs P; Páli S; Weymann A; Karck M; Szabó G
    J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):70-7. PubMed ID: 22914857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.
    Chester M; Seedorf G; Tourneux P; Gien J; Tseng N; Grover T; Wright J; Stasch JP; Abman SH
    Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L755-64. PubMed ID: 21856817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
    Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.
    Chester M; Tourneux P; Seedorf G; Grover TR; Gien J; Abman SH
    Am J Physiol Lung Cell Mol Physiol; 2009 Aug; 297(2):L318-25. PubMed ID: 19465519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice.
    Harloff M; Prüschenk S; Seifert R; Schlossmann J
    Br J Pharmacol; 2022 Jun; 179(11):2460-2475. PubMed ID: 33651375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.
    Meurer S; Pioch S; Pabst T; Opitz N; Schmidt PM; Beckhaus T; Wagner K; Matt S; Gegenbauer K; Geschka S; Karas M; Stasch JP; Schmidt HH; Müller-Esterl W
    Circ Res; 2009 Jul; 105(1):33-41. PubMed ID: 19478201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
    Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat.
    Surmeli NB; Marletta MA
    Chembiochem; 2012 May; 13(7):977-81. PubMed ID: 22474005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of soluble guanylate cyclase activation on heart transplantation in a rat model.
    Loganathan S; Korkmaz-Icöz S; Radovits T; Li S; Mikles B; Barnucz E; Hirschberg K; Karck M; Szabó G
    J Heart Lung Transplant; 2015 Oct; 34(10):1346-53. PubMed ID: 26210750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats.
    Geschka S; Kretschmer A; Sharkovska Y; Evgenov OV; Lawrenz B; Hucke A; Hocher B; Stasch JP
    PLoS One; 2011; 6(7):e21853. PubMed ID: 21789188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.
    Sharina IG; Sobolevsky M; Papakyriakou A; Rukoyatkina N; Spyroulias GA; Gambaryan S; Martin E
    Br J Pharmacol; 2015 May; 172(9):2316-29. PubMed ID: 25536881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.
    Korkmaz S; Radovits T; Barnucz E; Hirschberg K; Neugebauer P; Loganathan S; Veres G; Páli S; Seidel B; Zöllner S; Karck M; Szabó G
    Circulation; 2009 Aug; 120(8):677-86. PubMed ID: 19667237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide sensitive guanylyl cyclase activity decreases during cerebral postnatal development because of a reduction in heterodimerization.
    Haase N; Haase T; Seeanner M; Behrends S
    J Neurochem; 2010 Jan; 112(2):542-51. PubMed ID: 19895661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
    Reinhart GA; Harrison PC; Lincoln K; Chen H; Sun P; Hill J; Qian HS; McHugh MC; Clifford H; Ng KJ; Wang H; Fowler D; Gueneva-Boucheva K; Brenneman JB; Bosanac T; Wong D; Fryer RM; Sarko C; Boustany-Kari CM; Pullen SS
    J Pharmacol Exp Ther; 2023 Mar; 384(3):382-392. PubMed ID: 36507845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the nitric oxide-soluble guanylate cyclase system and natriuretic peptide receptor system in placentas of pregnant Dahl salt-sensitive rats.
    Takushima S; Nishi Y; Nonoshita A; Mifune H; Hirata R; Tanaka E; Doi R; Hori D; Kamura T; Ushijima K
    J Obstet Gynaecol Res; 2015 Apr; 41(4):540-50. PubMed ID: 25370989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NO- and haem-independent soluble guanylate cyclase activators.
    Schmidt HH; Schmidt PM; Stasch JP
    Handb Exp Pharmacol; 2009; (191):309-39. PubMed ID: 19089335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
    Shea CM; Price GM; Liu G; Sarno R; Buys ES; Currie MG; Masferrer JL
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F148-F159. PubMed ID: 31608671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.